Vestor Capital’s Clearside Biomedical CLSD Stock Holding History

Vestor Capital’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-600	Closed	-$54K	–	236
2021 Q3	$54K	Hold	600	–	–	0.01%	203
2021 Q2	$44K	Buy	+600	New	+$27.9K	﹤0.01%	208

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vestor Capital's CLSD Position: Q4 2021 in Review

Vestor Capital sold out of Clearside Biomedical (CLSD) in Q4 2021, closing a stake of 600 shares — an estimated $54K sold.

Vestor Capital first reported a position in CLSD in Q2 2021 and held it in 2 quarters. The position peaked at $54K in Q3 2021. 67 funds tracked by Wall St. Rank hold CLSD as of Q4 2021.

Vestor Capital reported no remaining Clearside Biomedical position as of Q4 2021 after selling out during the quarter.
Vestor Capital sold 600 Clearside Biomedical shares in Q4 2021, an estimated $54K.
Vestor Capital first reported a position in Clearside Biomedical in Q2 2021 and held it in 2 quarters.
Vestor Capital's Clearside Biomedical position peaked at $54K in Q3 2021.
67 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2021.

Based on Vestor Capital's 13F filing for Q4 2021, filed 11 Feb 2022.